Isoray (NYSEAMERICAN:ISR) Coverage Initiated by Analysts at Northland Securities

Northland Securities began coverage on shares of Isoray (NYSEAMERICAN:ISR) in a research report report published on Tuesday, The Fly reports. The brokerage issued an outperform rating and a $1.25 price objective on the healthcare company’s stock.

Separately, Zacks Investment Research raised Isoray from a sell rating to a hold rating in a research report on Thursday, July 15th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Isoray has a consensus rating of Buy and an average target price of $1.67.

Shares of NYSEAMERICAN:ISR opened at $0.72 on Tuesday. The company has a market cap of $101.57 million, a price-to-earnings ratio of -14.36 and a beta of 1.02. Isoray has a 12-month low of $0.35 and a 12-month high of $2.81. The stock’s fifty day moving average is $0.45.

Institutional investors and hedge funds have recently modified their holdings of the company. Walleye Capital LLC acquired a new stake in shares of Isoray in the 1st quarter valued at about $26,000. Renaissance Technologies LLC boosted its stake in Isoray by 141.8% during the 1st quarter. Renaissance Technologies LLC now owns 3,260,228 shares of the healthcare company’s stock valued at $3,554,000 after purchasing an additional 1,911,696 shares during the last quarter. BlackRock Inc. boosted its stake in Isoray by 163.1% during the 1st quarter. BlackRock Inc. now owns 3,040,560 shares of the healthcare company’s stock valued at $3,315,000 after purchasing an additional 1,884,898 shares during the last quarter. State Street Corp boosted its stake in Isoray by 4,807.3% during the 2nd quarter. State Street Corp now owns 519,042 shares of the healthcare company’s stock valued at $414,000 after purchasing an additional 508,465 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Isoray by 13.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,119,070 shares of the healthcare company’s stock valued at $892,000 after purchasing an additional 134,843 shares during the last quarter. Institutional investors own 12.46% of the company’s stock.

Isoray Company Profile

IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.

Read More: How to invest in blue-chip stocks

The Fly logo

Analyst Recommendations for Isoray (NYSEAMERICAN:ISR)

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.